Description
Kalorama’s 2nd edition of The World Cardiovascular Drugs Market, in its 2nd edition, will steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments.
Analyst Mary Ann Crandall considers both the exisiting products and the pipeline in this comprehensive market study. The following market segments are covered:
- Cardiac Glycosides and Positive Inotropic Agents
- Antihypertensive Agents (ACE Inhibitors, Angiotensin II Receptor Antagonists, Adrenergic Blockers, Beta Blockers, Calcium Channel Blockers, Combinations)
- Antiarrhythmic Agents (Class I, Class II, Class III)
- Vasodilators and Peripheral Vasodilator Agents
- Antihyperlipidemic Agents (Bile Acid Sequestrants, Fibric Acid Derivatives, Statins, Nicotonic Acid)
- Blood Modifiers (Anticoagulants, Antiplatelets, Thrmbolytics)
- Diuretic Agents (Carbonic Anhydrase Inhibitors, Loop, Potassium-Sparing, Thiazides)
- Other Cardiovascular Agents
Specific diseases and disorders discussed include:
- Angina
- Arrhythmia
- Atherosclerosis
- Congestive heart failure
- Coronary artery disease
- Hypertension
- Myocardial infarction
- Other disorders
The report details the various categories of cardiovascular drugs and describes U.S. and non-U.S. markets in each of the specific cardiovascular drug areas. Revenues are considered in each subsegment according to type of drug. In addition, top products in each category are reviewed. The report also covers market drivers and trends that are influencing the market, including:
- Obesity Epidemic and Heart Disease
- Statin use
- Inflammation Reduction
- Unique Drug Combinations
- Hormone Therapy and Cardiovascular Disease Risks
- CAD Risk Factor Differences in Sexes
- Women and Heart Disease
- OTC Statins
- Genetic Research and Wafarin Use
- Future Trends in the Pharmaceutical Arena
The report further identifies major market factors, which are discussed in detail, and a total market summary is presented.
All market data are presented at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2004. Historical data are provided for 2002 and 2003, and forecast data are provided for each of the years 2005 through 2009. Historical, base year, and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2004 base year.
As part of Kalorama’s trusted information-gathering process, information and analysis presented in this report are based on extensive interviews with senior management of top companies and other participants in the cardiovascular market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals.
Key information from published literature was used to conduct interviews with over 41 industry executives and product managers to validate and obtain expert opinion on current and future trends in the cardiovascular market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION
- Overview of the Cardiovascular System
- Heart
- Circulatory System
- Cardiac Cycle
- Isovolumic Contraction
- Ventricular Ejection
- Isovolumic Relaxation
- Coronary Circulation
- Cardiac Myocytes
- Contraction
- Calcium Role in Contraction
- Relaxation
- Cardiac Energy Metabolism
- Cardiac Output
- Cardiovascular Disorders
- Angina
- Incidence
- Etiology and Pathophysiology
- Risk Factors
- Arrhythmias
- Incidence
- Etiology and Pathophysiology
- Risk Factors
- Atherosclerosis
- Incidence
- Etiology and Pathophysiology
- Risk Factors
- Congestive Heart Failure
- Incidence
- Etiology and Pathophysiology
- Risk Factors
- Coronary Artery Disease
- Incidence
- Etiology and Pathophysiology
- Risk Factors
- Hypertension
- Incidence
- Etiology and Pathophysiology
- Risk Factors
- Myocardial Infarction
- Incidence
- Etiology and Pathophysiology
- Risk Factors
- Effects of Aging
- Demographics
- Disease Management
CHAPTER THREE: ISSUES AND TRENDS
- Obesity Epidemic and Heart Disease
- Statin use
- Inflammation Reduction
- Unique Drug Combinations
- Hormone Therapy and Cardiovascular Disease Risks
- CAD Risk Factor Differences in Sexes
- Women and Heart Disease
- Otc Statins
- Genetic Research and Warfarin Use
- Future Trends in the Pharmaceutical Arena
CHAPTER FOUR: PRESCRIPTION CARDIAC GLYCOSIDE AND IONTROPIC DRUGS
- Overview of Cardiac Glycosides and Inotropic Drugs
- Description of Products
- Market Size and Growth World Market
- Research and Development
- Competitive Analysis
CHAPTER FIVE: PRESCRIPTION ANTIHYPERTENSIVE DRUGS
- Overview
- Description of Products
- ACE Inhibitors
- Angiotensin II Receptor Antagonists
- Adrenergic Blockers
- Beta Blockers
- Recent Additions
- Calcium Channel Blockers
- Combinations
- New Developments
- Market Size and Growth
- World Market
- Research and Development
- Nebivolol
- CS- 8663
- Volibris
- Atacand Plus
- Clevidipine
- Coreg CR Plus ACE Inhibitor
- Darusentan
- Competitive Analysis
CHAPTER SIX: PRESCRIPTION ANTIARRHYTHMIC DRUGS
- Overview
- Description of Products
- Class I
- Class II
- Class III
- Market Size and Growth
- World Market
- Research and Development
- Tedasamil (Pulzium)
- RSD 1235 (vernakalant)
- Apixaban
- Bay 59-7939
- Dronedarone (Multaq)
- Idraparinux
- Tecadenoson
- Competitive Analysis
CHAPTER SEVEN: VASODILATOR AND PERIPHERAL VASODILATOR DRUGS
- Overview
- Description of Products
- Coronary Vasodilators
- Natriuretic Peptides
- Peripheral Vasodilators
- Recent Developments
- Market Size and Growth
- World Market
- Research and Development
- Competitive Analysis
CHAPTER EIGHT: PRESCRIPTION ANTIHYPERLIPIDEMIC DRUGS
- Overview
- Description of Products
- Bile Acid Sequestrants
- Fibric Acid Derivatives
- HMG-CoA Reductase Inhibitors (Statins)
- Nicotinic Acid
- Market Size and Growth
- World Market
- Research and Development
- LCP-FenoChol
- Synordia
- Acomplia
- Actos
- MK 0524A, MK0524B
- Pravastatin and Fenofibrate Combination
- AGI-`067
- ABT-335
- Apo-I Milano (ETC-216)
- ETC-642
- FM-VP4
- Competitive Analysis
CHAPTER NINE: PRESCRIPTION BLOOD MODIFIER DRUGS
- Overview
- Description of Products
- Anticoagulants
- Antiplatelets
- Thrombolytics
- New Developments
- Market Size and Growth
- World Market
- Research and Development
- Arixtra
- Exanta
- Cangrelor
- (Prasugrel) CS-747
- Integrilin
- Competitive Analysis
CHAPTER TEN: PRESCRIPTION DIURETIC DRUGS
- Overview
- Description of Products
- Carbonic Anhydrase Inhibitors
- Loop
- Potassium-Sparing
- Thiazides
- Market Size and Growth
- World Market
- Research and Development
- Competitive Analysis
CHAPTER ELEVEN: PRESCRIPTION OTHER CARDIOVASCULAR DRUGS
- Overview
- Description of Products
- Market Size and Growth
- World Market
- Research and Development
- Thelin
- Remodulin IV
- Ambrisentan (Letairis)
- Celacade
- Tadalafil
- Tolvaptan
- DITPA
- Competitive Analysis
CHAPTER TWELVE: WORLD MARKET SUMMARY
- Overview
- Total Market Size and Forecast
- Competitor Analysis
CHAPTER THIRTEEN: CORPORATE PROFILES
- Abbott Laboratories
- AStellas Pharma, Inc.
- Astra Zeneca
- Bayer Schering Pharma
- Biovail Corporation
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo Pharmaceuticals
- Eli Lilly and Company
- Genentech, Inc.
- GlaxoSmithKline
- MERCK & COMPANY INC
- Novartis International AG
- Pfizer, Inc.
- Roche
- Sanofi-Aventis
- Takeda Pharmaceuticals
- Emerging Cardiovascular Companies
- Cardiome Pharma Corporation
- Inotek Pharmaceuticals Corporation
APPENDIX: COMPANY DIRECTORY
TABLE OF EXHIBITSEXECUTIVE SUMMARY
- Table 1-1: Total World Prescription Cardiovascular Drug Market 2004-2011
- Figure 1-1: Total World Prescription Cardiovascular Drug Market 2004-2011
- Table1-2: World Market for Prescription
- Cardiovascular Drugs Revenues and Segments of Participation by Major Areas of Participation 2006
- Figure 1-2: World Market for Prescription Cardiovascular Drugs Revenues and Segments of Participation by Major Areas of Participation 2006
CHAPTER TWO: INTRODUCTION
- Table 2-1: U.S. Prevalence, Incidence and Mortality of Selected Cardiovascular Conditions
CHAPTER FOUR: PRESCRIPTION CARDIAC GLYCOSIDE AND IONTROPIC DRUGS
- Table 4-1: Marketed Cardiac Glycosides and Inotropic Drugs
- Table 4-2: Total World Cardiac Glycoside & Inotropic Drug Market 2004-2011
- Figure 4-1: Total World Cardiac Glycoside & Inotropic Drug Market 2004-2011
- Table 4-3: Cardiac Glycosides and Inotropic Agents in Development
- Table 4-4: Total Global Market for Cardiac Glycoside & Inotropic Drugs, Revenues and Market Share by Supplier 2006
- Figure 4-2: Total Global Market for Cardiac Glycoside & Inotropic Drugs, Market Share by Leading Supplier 2006
CHAPTER FIVE: PRESCRIPTION ANTIHYPERTENSIVE DRUGS
- Table 5-1: Marketed ACE Inhibitors
- Table 5-2: Marketed Angiotensin II Receptor Antagonists
- Table 5-3: Marketed Adrenergic and Beta Blockers
- Table 5-4: Marketed Calcium Channel Blockers
- Table 5-5: Marketed Combination and Other Antihypertensives
- Table 5-6: Total World Prescription Antihypertensive Drug Market 2004-2011
- Figure 5-1: Total World Prescription Antihypertensive Drug Market 2004-2011
- Table 5-6: Total World Prescription Antihypertensive Drug Market by Type 2004-2011
- Figure 5-2: Total World Prescription Antihypertensive Drug Market by Type 2006
- Table 5-7: Hypertensive Drugs in Development
- Table 5-8: Total Global Market for Prescription Antihypertensive Drugs, Revenues and Market Share by Supplier 2006
- Figure 5-9: Total Global Market for Prescription Antihypertensive Drugs, Market Share by Leading Supplier 2006
CHAPTER SIX: PRESCRIPTION ANTIARRHYTHMIC DRUGS
- Table 6-1: Marketed Antiarrhythmic Drugs
- Table 6-2: Total World Prescription Antiarrhythmic Drug Market 2004-2011
- Figure 6-1: Total World Prescription Antiarrhythmic Drug Market 2004-2011
- Table 6-3: Antiarrhythmic Drugs in Development
- Table 6-4: Total Global Market for Prescription Antiarrhythmic Drugs, Revenues and Market Share by Supplier 2006
- Figure 6-3: Total Global Market for Prescription Antiarrhythmic Drugs, Market Share by Leading Supplier 2006
CHAPTER SEVEN: VASODILATOR AND PERIPHERAL VASODILATOR DRUGS
- Table 7-1: Marketed Vasodilator and Peripheral Vasodilator Drugs
- Table 7-2: Total World Vasodilator and Peripheral Vasodilator Drugs Market 2004-2011
- Figure 7-2: Total World Vasodilator and Peripheral Vasodilator Drugs Market 2004-2011
- Table 7-3: Vasodilator and Peripheral Vasodilator Drugs in Development
- Table 7-4: Total Global Market for Vasodilator and Peripheral Vasodilator Drugs Revenues and Market Share by Supplier 2006
- Figure 7-4: Total Global Market for Vasodilator and Peripheral Vasodilator Drugs Market Share by Leading Supplier 2006
CHAPTER EIGHT: PRESCRIPTION ANTIHYPERLIPIDEMIC DRUGS
- Table 8-1: Marketed Antihyperlipidemic Drugs
- Table 8-2: Total World Prescription Antihyperlipidemic Drugs Market 2004-2011
- Figure 8-1: Total World Prescription Antihyperlipidemic Drugs Market 2004-2011
- Table 8-3: Antihyperlipidemic Drugs in Development
- Table 8-4: Total Global Market for Prescription Antihyperlipidemic Drugs Revenues and Market Share by Supplier 2006
- Figure 8-2: Total Global Market for Prescription Antihyperlipidemic Drugs Market Share by Leading Supplier 2006
CHAPTER NINE: PRESCRIPTION BLOOD MODIFIER DRUGS
